Loading clinical trials...
Loading clinical trials...
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
Conditions
Interventions
Durvalumab (Cohort 1-3)
External Beam Radiotherapy (EBRT)
+6 more
Locations
12
United States
BCG Oncology
Phoenix, Arizona, United States
Stanford University
Stanford, California, United States
Rush University Medical Cneter
Chicago, Illinois, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Start Date
November 21, 2017
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2027
Last Updated
April 15, 2026
NCT05889195
NCT06257264
NCT07206225
NCT06857175
NCT04693377
NCT06770582
Lead Sponsor
Noah Hahn, M.D.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions